Besides making insulin, the pancreas makes various digestive enzymes that allow us to digest food, and delivers those enzymes to the intestinal tract via a series of channels
Frequently Asked Questions Do you refrigerate retatrutide
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer significant clinical benefits in treating type 2 diabetes and obesity
For MOTS-c, research protocols discussed in investigational contexts vary widely, but often involve subcutaneous administration of 5-15 mg, 2-3 times weekly

To be eligible, a patient must need a GLP-1 medication for weight loss or maintaining weight reduction according to specific criteria, as follows: BMI of 35 or above at the time of GLP-1 initiation BMI of 30 or above at the time of GLP-1 initiation with heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension despite treatment with two antihypertensive medications, or chronic kidney disease (stage 3a or above) BMI of 27 or higher with pre-diabetes, symptomatic peripheral artery disease, previous stroke, or history of myocardial infarction Patients with diagnoses for type 2 diabetes, moderate-to-severe obstructive sleep apnea, and/or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) are not eligible to receive GLP-1 medications through the Bridge Program, even if they meet the above-mentioned criteria
Obesity: Assessment and treatment across the care continuum, Annals of Medicine